logo
  • Über uns
    • Über uns
    • Führungsteam
    • Partnerschaften
    • Unsere Standorte
  • Technologie
    • Technologie
    • Produktion
    • Publikationen
  • Pipeline
  • Newsroom
    • News
    • Events
    • Downloads
  • Investor Relations
    • Überblick
    • Aktieninformation
    • Analysten-Coverage
    • Außerordentliche Hauptversammlung 2023
    • Finanzberichte
    • Corporate Governance
    • E-Mail Alert
  • Karriere
    • Werden Sie Teil der RNA people
    • Ausbildung
    • Aktuelle Stellenangebote
  • DE

Review Articles

mRNA: A novel Avenue to Antibody Therapy


by Sovereign

New Vaccine Technologies to Combat Outbreak Situations


by Sovereign

mRNA as novel technology for passive immunotherapy


by Sovereign

mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer


by Sovereign

A development, that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs


by Sovereign

A novel, disruptive vaccination technology, Self-adjuvanted RNActive® vaccines


by Sovereign

Developing mRNA-vaccine technologies


by Sovereign

mRNA: delivering an antitumor message


by Sovereign

Vaccination with messenger RNA


by Sovereign

RNA-based Therapies


by Sovereign

  • 1
  • 2